welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
study id #: NCT02420379
condition: Duchenne Muscular Dystrophy (DMD)
This is an open-label study to assess the safety, tolerability, efficacy and pharmacokinetics of eteplirsen in patients with early stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
mechanism of action: Exon-skipping to promote dystrophin production
last updated: August 01, 2020
start date: June 30, 2015
estimated completion: December 17, 2018
phase of development: Phase 2
size / enrollment: 33
Safety, including adverse event monitoring and routine laboratory assessments, will be followed on an ongoing basis for all patients.
Clinical efficacy, including functional tests and MRI, will be assessed at regularly scheduled study visits. Patients will undergo one baseline and one follow-up muscle biopsy.
Population and serial PK will be collected.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation [ Time Frame: Baseline up to 100 weeks ]
Adverse Event (AE) was any untoward medical occurrence in a participant that did not necessarily have a causal relationship with the study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Treatment emergent adverse events were events that developed or worsened during the on-treatment period (defined as time from first dose of study drug and up to 28 days after last dose of study drug [up to 100 weeks]) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.
- Number of Participants With Potentially Clinically Significant Laboratory Abnormalities Reported as TEAEs [ Time Frame: Baseline up to 100 weeks ]
Laboratory parameters included hematology, serum chemistry (SC), urinalysis and coagulation. Number of participants with at least one potentially clinically significant abnormal findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were clinically significant or not clinically significant. Clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.
- Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs [ Time Frame: Baseline up to 100 weeks ]
Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Number of participants with at least one potentially clinically significant abnormal vital signs findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were clinically significant or not clinically significant. Clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.
- Number of Participants With at Least One Abnormal Physical Examination Finding [ Time Frame: Baseline up to 100 weeks ]
Physical examinations, full and brief, were performed by the Investigator, a physician Sub-Investigator, or a Nurse Practitioner (if licensed in the state or province to perform physical examinations). Full physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; skin; lymph nodes; and musculoskeletal and neurological systems. Number of participants with at least one abnormal physical examination findings were reported. Abnormality in physical examinations was based on Investigator's discretion.
- Number of Participants With Abnormalities in Electrocardiograms (ECGs) Reported as TEAEs [ Time Frame: Baseline up to 96 weeks ]
Twelve-lead ECGs and Holter ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the participant was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel. Number of participants with at least one abnormalities in ECGs were reported as TEAEs.
- Number of Participants With Abnormalities in Echocardiograms (ECHO) Reported as TEAEs [ Time Frame: Baseline up to 96 weeks ]
Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study. Cardiac function events included cardiomegaly, tachycardia, and dyspnoea. The ECHO was reviewed and interpreted by medically qualified personnel. Number of participants with at least one abnormalities in ECHO were reported as TEAEs.
- Change From Baseline in Dystrophin Protein Levels Quantified by Western Blot at Week 96 [ Time Frame: Baseline, Week 96 ]
Change from baseline in dystrophin protein levels (in muscle biopsy samples) was determined by western blot.
- Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 96 [ Time Frame: Baseline, Week 96 ]
Change from baseline in dystrophin intensity levels (in muscle biopsy samples) was determined by Immunohistochemistry.
• Eligible Sexes: male
• Stable dose of oral corticosteroids for at least 12 weeks or has not received corticosteroids for at least 12 weeks.
• Intact right and left biceps muscles or two alternative upper arm muscle groups.
• Parent that is willing to provide consent and comply with study procedures.
• Use of any pharmacologic treatment (other than corticosteroids) within 12 weeks that may have an effect on muscle strength or function (e.g., growth hormone, anabolic steroids).
• Previous or current treatment with any other experimental treatments within 12 weeks or participation in any other clinical trial within 6 months.
• Major surgery within 3 months prior to the first dose of study drug, or planned surgery during this study which would interfere with the ability to perform study activities.
• Presence of other clinically significant illness.
Phase IIb Study of PRO045 in Subjects With Duchenne Muscular DystrophyThe purpose of the study is to see wheth...
Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for Duchenne Muscular Dystrophy (DMD): Clinical Update an...Objective: DMD, a rare, degenerative, X...
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyThe main purpose of this study is to tes...
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)HOPE-2 is a double-blind clinical trial ...
Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients wit...Capricor Therapeutics, Inc. (NASDAQ: CAP...
Results at 96 Weeks of a Phase IIb Extension Study of the Exon-Skipping Drug Eteplirsen in Patients with Duchenne Mu...Objective: The objective of this study ...
Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrop...To Assess the Activity and Safety of SMT...
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...
Roche Letter to the Duchenne CommunityBy now, many have heard about Pfizer's d...